Alzheimer's Flashcards

1
Q

is Alzheimer’s progressive or reversible

A

progressive and non reversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

onset of Alzheimer’s

A

insidious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what age is classified as early onset Alzheimer’s

A

<65

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

how may early onset Alzheimer’s presentation vary

A

may be atypical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

are genetic factors or environemental factors more important in the development of early onset/Alzheimer’s

A

early onset, thinking genetic factors - maybe a mutation

population risk for AD is more due to multifactorial - genes, environement etc

look at ice Berg triangle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

are females or males more likely to get Alzheimer’s

A

females

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

genetics of AD - which 3 mutations are associated

A
  • multifactorial, but increased risk with 1st degree relative (25%)
  • APP gene mutation - produces amyloid precuros protein, excess leads to formation of beta amyloid palques and tau tangles
  • PSEN genes
  • Inheriting Apoe4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

do lifestyle factors have an influence on the development of Alzheimer’s

A

yes, smoking midlife obesity, diet high in sat fats are risk factors

also, diabetes, smoking in mid-life, hypertension are found to be the greatest modifiable risk factors for dementia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

cerebrovascular disease and Alzheimer’s

A

is a strong risk factor for vascular dementia, which often overlaps with Alzheimer’s

diabetes increases the risk of both

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Down’s and Alzheimer’s

A

Down’s is assoicated with early onset Alzheimer’s

the presence of 3 copies of the APP gene on chromosome 21 accounts for this

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

which allele is a risk factor for Alzheimer’s

A

ApoE e4 allele

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

which 3 things point towards a familial cause o disease

A

early onset

atypical form

relatives affected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

senile plaques

A

EC deposits of amyloid beta in grey matter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how does amyloid beta form

A

mutations in the amyloid precursor protein leads to formation of abnormal amyloid beta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what do senile plaques do

A

Senile plaques cause an inflammatory process through microglial activation, cytokine formation and activation of complement cascade. Inflammation leads to formation of neuritic plaques à cell death.

Leads to cortical atrophy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are neurofibrillary tangles made of

A

abnormal aggregates of tau protein

17
Q

is the number of neurofibrillary tangles important in disease severity?

A

number of tangles roughly proportional to severity of disease and cognitive decline

18
Q

what happens to cholinergic neurotransmission

A

the collection of neurons that produce ACh (called the nucleus basalis of Meynert) is affected early on in the disease process - decreased levels of cholingeric neurotransmission

19
Q

what happens to glutamine transmission

A

there are changes to the NMDA receptors - results in overativation of glutamate - excito!!!

20
Q

what are important points to elicit from history

A
  • timeline of progression
  • how ADL are affected eg financial affairs and medications
21
Q

what are the 3 common presenting symptoms

A

loss of recent memory

difficulty with exectuve function

nominal dysphasia

22
Q

what other features are common

A
  • Disorientation (e.g. things getting lost at first – this could also be due to visuo-spatial dysfunction)
  • Apathy
  • Deficits in visuo-spatial function (e.g. impaired performance in clock-drawing) and driving become evident as the disease progresses
  • Features such as prosopagnosia (not recognizing familiar faces) and auto prosopagnosia tend to develop later
23
Q

do changes in personality occur?

A

later in disease, unlike in other dementias

24
Q

physical examination

A

unremarkable in early stages.

In advanced disease patients may appear sloppily dressed, confused, apathetic, disorientated.

25
Q

what is a good cognitive test to use initially

A

mini mental state examination

26
Q

what tests would be done to rule out other causes on diagnosis

A
  • FBC: to rule out anaemia
  • Metabolic panel
  • TSH – rule out hyper/hypothyroid associated dementia
  • Serum vitamin B12
  • CT – exclude SOL etc.
27
Q

what is seen on an MRI

A

generalised atrophy, temporal and lateral parietal predominance

compensatory dilation of ventricles

28
Q

what would examination of CSF show

A

increased tau level and decreased amyloid beta

29
Q

what is the first step of management

A

to provide education, support and resources to patient and family

30
Q

which risk factors must be addressed during management

A

vascular risk factors

31
Q

pharmacological management

A
  • Cholinesterase inhibitors (boost ACh):
    • Donepezil, Rivastigmine, Galantamine
  • Anti-glutaminergic treatment (NMDA blockers)
    • Memantine
32
Q

how do cholinesterase inhibitors work

A

Increase brain ACh levels by inhibiting breakdown by CNS acetylcholinesterase

33
Q

what benefit will cholinesterase inhibitors provide

A

they will not affect the underlying disease process, but will imrpove function and help pt maintain independece

34
Q

what other dementia forms are cholinesterase inhibtors used in

A

DLB, parkinson’s dementia

35
Q

how does memantine work

A

it is an antagonist of the NMDA receptors - inhibits excessive glutamine activity

36
Q

who would be prescribed memantine

A
  • Moderate AD who are intolerant of/contraindication to cholinesterase inhibitors
  • Add on drug to cholinesterase inhibitors for moderate/severe AD
  • Monotherapy in severe AD